TIZAF Projected Dividend Yield
Ord (New)/Tiziana Life Sciences PLC ( OTCBB : TIZAF )Tiziana Life Sciences is a biotechnology company that is focused on the discovery and development of molecules and related diagnostics. Co.'s lead product candidate in immunology is Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody in clinical development. In addition, Co. is accelerating development of another fully human monoclonal antibody anti-IL6R (TZLS-501) to treat acute inflammation resulting from infection with viral agents such as Coronaviruses. Co.'s lead product candidate in oncology is Milciclib (TZLS-201), which is an orally bioavailable, small molecule broad spectrum inhibitor of cyclin-dependent kinases and Src family kinase. 20 YEAR PERFORMANCE RESULTS |
TIZAF Dividend History Detail TIZAF Dividend News TIZAF Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend Amount (GBP) |
Total: |
0.0000 |